Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
2.100
-0.040 (-1.87%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Kyverna Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
96.6234.6537.7476.07
Short-Term Investments
189.3622.913.59-
Cash & Short-Term Investments
285.9857.5451.3276.07
Cash Growth
396.98%12.12%-32.53%-
Prepaid Expenses
4.623.121.931.02
Total Current Assets
290.660.6653.2577.09
Property, Plant & Equipment
10.6610.6112.447.81
Long-Term Deferred Charges
-2.5--
Other Long-Term Assets
3.391.421.230.59
Total Assets
304.6575.266.9285.49
Accounts Payable
4.624.361.450.77
Accrued Expenses
11.139.067.667.77
Current Portion of Leases
3.942.922.280.81
Current Unearned Revenue
---6
Other Current Liabilities
14.063.520.570.58
Total Current Liabilities
33.7619.8611.9515.93
Long-Term Leases
4.36.168.294.74
Long-Term Unearned Revenue
---1.03
Other Long-Term Liabilities
--0.011.33
Total Liabilities
38.0626.0220.2523.02
Additional Paid-In Capital
5304.641.710.53
Retained Earnings
-263.52-136.04-75.68-46.78
Comprehensive Income & Other
0.110-0.03-
Total Common Equity
266.59-131.4-74-46.25
Shareholders' Equity
266.5949.1846.6862.47
Total Liabilities & Equity
304.6575.266.9285.49
Total Debt
8.249.0810.565.56
Net Cash (Debt)
277.7448.4640.7670.51
Net Cash Growth
473.08%18.91%-42.20%-
Net Cash Per Share
7.2571.9589.48265.19
Filing Date Shares Outstanding
43.2143.120.550.27
Total Common Shares Outstanding
43.211.250.550.27
Working Capital
256.8540.8141.361.16
Book Value Per Share
6.17-105.11-133.91-173.96
Tangible Book Value
266.59-131.4-74-46.25
Tangible Book Value Per Share
6.17-105.11-133.91-173.96
Machinery
6.24.173.743.35
Leasehold Improvements
0.820.650.460.08
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q